AIM-listed Novacyt stated complete group income hit £94.7 million within the first half of 2021, up sharply from £63 million in the identical interval a 12 months in the past.
Novacyt stated the UK non-public testing market had “elevated considerably” throughout the interval and it had additionally secured a brand new contract with the WHO, in addition to exports to an extra eight international locations.
The agency stated it “expects continued robust development in non-public testing as markets and journey re-open and, because the Northern Hemisphere heads into winter, the potential for greater an infection charges will enhance the necessity for Covid-19 testing”.
Because the begin of 2020, the Anglo-French group which has workplaces in Camberley, Surrey has launched 16 new testing merchandise, and expects to launch an extra 10 by the tip of 2022.
The corporate stated it “believes it’s properly positioned to proceed to assist development throughout the second half of the 12 months”.
Shares in Novacyt rose greater than 10%, or 32.9p, to 334.9p.